Pilatus Biosciences offers a unique opportunity to invest early at an attractive valuation. Our innovative therapies are already drawing strong interest from global pharmaceutical leaders, positioning us for high-value licensing deals or early M&A exits. In today’s selective market, Pilatus stands out through scientific innovation, capital efficiency, and a clear path to value creation.


Investment Highlights
01. About Us
Pilatus Biosciences is a preclinical-stage biotech company pioneering first-in-class biologics targeting metabolic checkpoints to reprogram the tumor microenvironment (TME)
02. Novel Science
Differentiated Immunometabolism approach targeting growing Cancer Immunotherapy and Metabolic Disease market
03. Lead Pipeline: PLT012
PLT012, a humanized anti-CD36 antibody, has demonstrated preclinical efficacy and received FDA Orphan Drug Designation for Liver cancers.